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Anterior pituitary peptide hormones which circulate at
nanogram or picogram levels are readily measurable under
basal conditions by radioligand assay. In addition, functional
reserve may be further assessed by the use of specific
provocative tests 'aimed' at either hypothalamus, anterior
pituitary or the target organ. Some of these are briefly
outlined.
During the last decade the assessment of hypothalamic-
anterior pituitary-target organ function has been revolu-
tionised by the development of ~ghly sensitive and specific
assay techniques capable of measuring hormones in
amounts as low as 10'· to lO,12g, the circulating levels in
biological fluids. In addition, agents are now available
capable of provoking anterior pituitary and peripheral hor-
mone release by specific stimulation of the hypothalamus,
pituitary or target organs. Thus, not only can basal hor-
mone levels be accurately estimated, but the reserve of
the secreting organ can be assessed, often in specific
physiological terms. This paper deals in brief with the
principle of the newer assays used to measure circulating
hormone levels and then discusses these dynamic or pro-
vocative tests.
MEASUREMENT OF HORMONES IN
BIOLOGICAL FLUID
Fig. 1. Principles oil radioJiaand assay 'for senm or
plasma 'hormone levek. See text for details.
Steroid or peptide hormones are currently measured by
the radioligand technique (Fig. 1). This method depends
on competition between radioactively labelled and unla-
belled hormone for binding to any of a variety of binding
agents. An increasing amount of unlabelled hormone' dis-
places labelled hormone from the binding agent leading
to a reduction in radioactive hormone binding (B) and an
increase in free radioactive hormone (F). Various tech-
niques exist for measuring the ratio of B to F. This pro-
portionate drop of the radioactive bound fraction
(expressed as 8/F ratio) with increasing unlabelled hor-
mone (standard) may be plotted graphically as in the
luteinising hormone (LH) assay shown in Fig. 2. If an
unknown plasma or serum is substituted for standards and
the labelled hormone and binding agent kept constant, the
When hormones circulate in relatively high concentrations,
they are measured biochemically, e.g. the fluorometric
assay for plasma cortisol. However, most hormones, par-
ticularly the polypeptides, circulate at nanogram (10'· g)
or picogram (lO-"g) levels and more sensitive techniques
have to be employed. The traditional method of estimating
these circulating hormones was by biological assay, which
measured a biochemical or histological end-point of hor-
mone function. These techniques were relatively insensi-
tive, and specificity was often suspect as substances other
than the hormone occasionally simulated the biological
effects, as was found with the measurement of insulin-like
activity. The probable existence of hormone antagonists in
biological fluids also complicated this type of system.
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BJF obtained will reflect the quantity of hormone therein.
If the binding agent is an antibody to the appropriate hor-
mone, the technique is known as radio-immunoassay. This
is by far the most common type of radioligand system
currently in use.
The competitive protein binding assay employs circula-
ting hormone carrier proteins as binding agents, for
example hormone-binding protein in the measurement
of cortisol' or testosterone.' Recently, hormonal target tissue
has been used as the binding agent; the so-called radio-
receptor assay, as exemplified by the LH assay employing
interstitial cell fractions of rat testis.' This latter technique
is still experimental.
DYNAMIC PROVOCATIVE TESTS OF
ANTERIOR PITUITARY-TARGET ORGAN
FUNCTION
Fig. 3 illustrates the levels at which provocative function
tests might be carried out in relation to the hypothalamus, .
anterior pituitary and target organ. The hypothalamus
might be activated during sleep, by stress (e.g. insulin
hypoglycaemia), by non-specific peptides such as arginine,
biogenic amines like L-dopa or drugs influencing them
such as chlorpromazine, or inactive analogues of peri-
pheral hormones which may interfere with the hypothala-
mic feedback mechanisms and so discharge the appropriate
hypothalamic releasing factor, for example clomiphene
citrate. Blockade of peripheral hormone synthesis may
likewise release the hypothalamus and anterior pituitary
from the negative feedback effects of that hormone, and
so elevate its precursors, as exemplified by the effects of
metyrapone on cortisol synthesis.
Provocative tests may stimulate the anterior pituitary
directly to release its appropriate hormone. The recent
discovery of the peptide sequence of thyrotrophin-releasing
factor (TRF)' or the FSHjLH-releasing factor (FSHJLH-
RF)' has enabled these peptides to be synthesised. Both
are now available for provocative testing of pituitary
function, respectively testing the release of TSH and pro-
lactin, and the gonadotrophic hormones LH and FSH.
The administration of pituita,ry hormones may directly
stimulate the target organ and so test that organ's respon-
siveness to the pituitary. Examples of such provocative
tests include the administration of bovine TSH to elevate
the thyroid 1311 uptake, the use of ACTH (or more recently,
synacthen, the synthetic I - 24 peptide) to stimulate cortisol
release from the adrenal, and the administration of
human chorionic gonadotrophin (HCG), which has a
biological action very similar to that of LH, to test testi-
cular response as measured by plasma testosterone levels.
These tests will be considered in greater detail.
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Synthetic TRF, FSH/LH RF
ACTH, TSH, HCG (LH)
- - - - - - - - - - - - - Peripheral hormone Metyrapone (blockade of cortisol synthesis)
Fig. 3. Provocative tests of the Ilypotbabmic-pituibry-target organ axis.

















Fig. 8. Pbysio1ogical rationale of, aDd a normal senan
thyrotrophin (TSH) and tri-iodothyronine (T.) response to
200 ILK iIltraveoous synthetic 'thyrotroPhin-releasing factor
(TRF).
TRF-TSH Test
days preceding the day of, and the day succeeding, metyra-
pone administration. A typically normal test is shown in
Fig. 7.
As urine collections are time-consuming and often
inaccurate, and as completeness of metyrapone-induced
blockade of cortisol synthesis is never certain, a modifica-
tion of the test has recently been proposed' in which
plasma cortisol and 11-DOC are measured simultaneously
just before and 4 hours after completion of metyrapone
administration. The response of I I-DOe .can thus be
assessed against the drop in plasma cortisol.
The hypothalamic thyrotrophin-releasing factor has
recently been identified as a tripeptide, pyroglutamyl-
histadyl-prolineamide: This has subsequently been synthe-
sised' and can be used for physiological studies and the
clinical testing of pituitary-thyroid function in man, as it
directly stimulates the anterior pituitary to release TSH.
The stimulated thyroid subsequently releases T. and T.,
the latter rising inconsistently. TRF is usually given by the
intravenous route in a single injection of 200 ",g. Side-
effects are minor and transient, and include flushing, nausea
and a desire to micturate. Blood is taken basally for
plasma immunoreactive TSH and tri-iodothyronine (Ta).
Twenty, 40 and 60 minutes after administration of TRF,
blood is sampled once more for TSH and again at 3 and
5 hours for Ta. A typically normal result is shown in Fig.
8. TSH rises acutely, peaks 20 minutes after TRF, and
drops progressively towards basal levels. Plasma Ta only
rises after that time, achieving a peak between 3 and 5
hours.
The test is useful in the assessment of pituitary-thyroid
reserve in patients with pituitary tumours or suspected
hypopituitarism,' the responses being low. In hypothalamic
hypothyroidism, TSH rise may be delayed but is otherwise
normal.' In primary (thyroid) hypothyroidism, TSH is
elevated with a hyper-response to TRF,a. with low T. levels
throughout the test. In hyperthyroidism, TSH is usually
































Fig. 7. Physiological rationale Of, and a uonnaI urinary
17-oxogenic steroid response to blockade. of cortisol syn-
thesis wida oral metyrapone.
Fig. 6. Physiological rationale of, and a normal senml
luteinising hormone (LH) and testosterone response to
oral clomiphene citrate administration.
The demonstration of a simultaneous rise in plasma
testosterone provides additional evidence of the testes'
ability to respond to endogenous LH. The hypothalarnic-
pituitary-gonadal axis in males may therefore be conveni-
cently assessed in a single test.
effect of oestrogen feedback. As a consequence, levels of
plasma LH rise gradually. Clomiphene citrate is given
orally in a dose of 3 mg/kg/day (average 200 mg/day) for
10 days and blood is taken for LH immunoassay at the
onset and during the course of the test. A typically normal
response is shown in Fig. 6.
Metyrapone Test
Metyrapone, given orally (750 mg every 4 hours for
6 doses), blocks 11-hydroxylation of cortisol and lowers
plasma cortisol levels. There is a slow rise of ACTH with
an increase in the immediate precursor of cortisol, 11-
deoxycortisol (11-DOq, which is metabolised to com-
pounds measurable as urinary 17-hydroxycorticoids or 17-
oxo(keto)-genic steroids. The increase in these metabolites
implies the integrity of the hypothalamic-pituitary-adrenal
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as its secretion is being maximally suppressed by the high
endogenous Ta and T, released by the hyperactive thyroid
gland. This test has occasionally been helpful in subtle
forms of hyperthyroidism where conventional studies may
be negative, for example in the newly-recognised condition
of tri-iodothyronine (Ta) thyrotoxicosis.
Quite unexpectedly, HPrl has been found to rise after
TRF," although the physiological relevance of this is not
yet cleaL The same blood samples used in the TSH esti-
mation may be assayed for HPrl, providing yet another
useful and sensitive test of anterior pituitary function.
Basal HPrl is elevated, and the response to TRF exagge-
rated in many patients with the amenorrhoea-galactorrhoea
syndrome, whether drug-induced or associated with hypo-
thalamic or pituitary tumours.
somewhat elevated in the luteal phase, and greatest just
before ovulation. I'
This test is useful in children with delayed puberty."
If endocrine function is normal, there is nearly always
a gonadotrophin response to FSH/LH-RF. whereas with
organic hypothalamic or pituitary disease, the response is
usually blunted or absent. It is of interest that even in the
presence of hypothalamic disturbance, poor gonadotrophin
release is often found. Presumably some prior activation
by endogenous FSHjLH-RF is necessary in order to prime
the pituitary to respond to the effect of the exogenously
administered releasing factoLl3 Possibly the administration
of repeated doses or of a long-acting FSH/LH-RF might
distinguish between hypothalamic and pituitary disease, but
as yet such studies have not been forthcoming.
FSH/LH·RF Test Pituitary Trophic Hormone Stimulation Tests
The peptide sequence of FSHjLH-releasing factor (FSH/
LH-RF) was recently announced' and the decapeptide has
been synthesised." Like TRF, it is a direct stimulus to the
pituitary gland and may be diagnostically helpful in
diseases of the hypothalamic-pituitary-gonadal axis. In
combination with the clomiphene test, it should theoreti-
cally help to delineate the precise site of any lesion, as in
hypothalamic diseases the response of the pituitary gona-
dotrophins to FSH/LH-RF should be normal (which in
practice it rarely is), whereas clomiphene would be in-
effective. FSH/LH-RF (lOO ,u.g) is given intravenously (25
U O in children) and blood taken basally and 20, 60 and
'120 minutes after the injection for plasma immuno-
reactive LH and FSH. A typical result is shown in Fig. 9.
The measurement of the thyroid l3'I uptake before and
after bovine TSH (10 units intramuscularly per day for
4 days) is useful to differentiate primary from secondary
hypothyroidism in patients with clinical and biochemical
evidence of myxoedema. This test has largely been replaced
by the immunoassay of a single plasma sample for TSH,
which is elevated in primary (thyroid) hypothyroidism and
low in hypothalamic or pituitary disease. A typically nor-


















Fig. 9. Physiological rationale of, and a normal serum
follicle-stimulating hormone (FSH) and LH response to
100 .ug intravenous synthetic FSH/LH·RF.
LH and FSH rise abruptly at 20 minutes (LH responding
to a much greater extent) and gradually return towards
normal values." Only one gonadotrophin-releasing factor
may be present; its ability to stimulate either LH or FSH
possibly varies with the circulating oestrogen leveL" Very
low oestrogen levels favour FSH and slightly higher levels
favour LH response to the decapeptide. In adolescents or
adults therefore LH is more elevated than FSH after the
same 'dose of FSH/LH-RF, as illustrated, whereas in in-
fants FSH secretion is favoured." LH and FSH responses
may 'also vary with the stage in the menstrual cycle, being
Fig. 10. Physiological rationale of, and a normal increase
in thyroid "'1 uptake in response to, stimulation by bovine
TSH 10 IV daily intramuscularly.
ACTH, given either intramuscularly or as a 4-6-hour
intravenous infusion, has for long been used as a test of
adrenal responsiveness. Recently ACTH extract has been
replaced by the synthetic ACTH 1 - 24 amino acid pep-
tide (synacthen), given intravenously or intramuscularly in
a dose of 0,25 mg. Blood is taken basally and 30 and 60
minutes for cortisol estimation. A normal response is
shown in Fig. 11. The test is simple and as the fluoro-
metric assay for cortisol" is widely available, it is ideally
suited to the screening of patients with suspected Addison's
disease. Tt may be used as an outpatient procedure.
Human chorionic gonadotrophin (HCG) has a similar
action to LH and can be used as a provocative test of
7
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Fig. 11. Physiological rationale of, and plasma cortisol




and 5 and blood taken for plasma testosterone on days
0, 2, 4 and 6. Basal testosterone levels should at least
double if normal testicular Leydig cell responsiveness is
present.
This paper is not comprehensive and deals exclusively
with provocative tests of pituitary-target organ reserve.
Other tests of the hypothalamic-pituitary pathway, for
example assessment of the nyctohemeral rhythm of cor-
tisol secretion, or tests of pituitary suppressibility in
diseases of pituitary hyperfunction, may be very valuable.
Indirect tests may be useful, for example the oral water
load test and its response to hydrocortisone in the screen-
ing of suspected Addison's disease in areas where no bio-
chemical facilities exist. Finally, radiology is crucial in the
localisation of tumours of the pituitary or target organs.



















fjg. 12. Physiological rationale of, and normal plasma
testosterone response to the stimulus of intramuscular
HCG 2 000 IU on alternate days.
testicular function. There are many dose regimens recom-
mended for this test and one is shown in Fig. 12, where
HCG 2000 units is given intramuscularly on days 1, 3
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